日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.

肿瘤微环境中的 CD8+ T 细胞调节乳腺癌对内分泌治疗的反应。

Napolitano Fabiana, Wang Yunguan, Sudhan Dhivya R, Gonzalez-Ericsson Paula I, Formisano Luigi, Unni Nisha, Shakeel Shahbano, Zhu James Z, Ahuja Khushi, Guo Lei, Chica-Parrado María Rosario, Matsunaga Yuki, Luna Pamela, Lin Chang-Ching A, Uemoto Yasuaki, Lee Kyung-Min, Ma Hongli, Evans Nathaniel J, Servetto Alberto, Mendiratta Saurabh, Barnes Spencer D, Bianco Roberto, Fang Yisheng V, Xu Lin, Lee Jeon, Wang Tao, Balko Justin M, Mills Gordon B, Labrie Marilyne, Hanker Ariella B, Arteaga Carlos L

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.

从临床到实验室的转化分析:激素受体阳性转移性乳腺癌中 NF1 改变和 CDK4/6 抑制剂耐药性

Lloyd Maxwell R, Chica-Parrado Rosario, Weipert Caroline M, Knepper Todd C, Podany Emily L, Napolitano Fabiana, Ye Dan, Lin Chang-Ching, Uemoto Yasuaki, Liao Jiemin, Wegrzyn Claire, Walko Christine M, Ryan Lianne Y, Keenan Jennifer C, Medford Arielle J, Liu Shiyuan A, Wulf Gerburg M, Clifton Katherine K, Ma Cynthia X, Han Hyo S, Zhang Nicole, Ellisen Leif W, Bardia Aditya, Arteaga Carlos L, Hanker Ariella B, Wander Seth A

ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.

ESR1 Y537S 和 D538G 突变导致雌激素受体阳性乳腺癌对 CDK4/6 抑制剂产生耐药性

Lin Chang-Ching A, Chica-Parrado María Rosario, Unni Nisha, Jaeger Ellen, Fang Yisheng V, Guo Lei, Napolitano Fabiana, Luna Pamela, Harris Michelle, Chao Calvin, Xu Lin, Arteaga Carlos L, Hanker Ariella B

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.

选择性降解 FGFR1/2 可克服 FGFR1/2 改变的 ER+ 乳腺癌的抗雌激素耐药性

Uemoto Yasuaki, Lin Chang-Ching A, Wang Bingnan, Ye Dan, Fang Yisheng V, Bikorimana Emmanuel, Napolitano Fabiana, Chica-Parrado Maria Rosario, Li Cheung, Mendiratta Saurabh, Chen Chuo, Hanker Ariella B, Arteaga Carlos L

Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.

CDK4/6 和 AKT 的联合抑制对三阴性乳腺癌的管腔雄激素受体 (LAR) 亚型具有高度疗效

Chica-Parrado María Rosario, Kim Gun Min, Uemoto Yasuaki, Napolitano Fabiana, Lin Chang-Ching, Ye Dan, Bikorimana Emmanuel, Fang Yisheng, Lee Kyung-Min, Mendiratta Saurabh, Hanker Ariella B, Arteaga Carlos L

Overcoming Endocrine Resistance in Breast Cancer

克服乳腺癌的内分泌耐药性

Hanker, Ariella B; Sudhan, Dhivya R; Arteaga, Carlos L

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

PI3K抑制剂临床开发面临的挑战:提高其在实体瘤治疗中疗效的策略

Hanker, Ariella B; Kaklamani, Virginia; Arteaga, Carlos L

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer

通过转录组和蛋白质组分析,鉴定 PIK3CA (H1047R) 在 HER2/ER 阳性乳腺癌中改变的 eIF4G、STAT3 和 Hippo 通路的异常调控

Cheng, Feixiong; Zhao, Junfei; Hanker, Ariella B; Brewer, Monica Red; Arteaga, Carlos L; Zhao, Zhongming

Mouse models and anti-HER2 therapies

小鼠模型和抗HER2疗法

Hanker, Ariella B; Cook, Rebecca S; Arteaga, Carlos L